A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers

BACKGROUND: Inhibition of interleukin (IL)-13, a Type 2 inflammatory mediator in asthma, improves lung function and reduces exacerbations; however, more effective therapies are needed. A subset of asthma patients also exhibits elevated IL-17, which is associated with greater disease severity, neutro...

Descripción completa

Detalles Bibliográficos
Autores principales: Staton, Tracy L., Peng, Kun, Owen, Ryan, Choy, David F., Cabanski, Christopher R., Fong, Alice, Brunstein, Flavia, Alatsis, Kathila R., Chen, Hubert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323662/
https://www.ncbi.nlm.nih.gov/pubmed/30616547
http://dx.doi.org/10.1186/s12890-018-0763-9

Ejemplares similares

Ejemplares similares